Mandate

Vicore Pharma Holding acquires INIM Pharma

Vinge has advised the shareholders of INIM Pharma in connection with the sale of the company to Vicore Pharma Holding, which is listed on First North.

INIM Pharma develops a new local treatment of severe and unusual forms of lung disease such as idiopathic lung fibrosis. 

The acquisition is performed as an issue in kind corresponding to a dilution of 35.8 per cent. HealthCap VII LP owns 85 per cent of INIM and following the acquisition HealthCap VII LP will hold approximately 30.4 per cent of the shares in Vicore Pharma Holding.

The transaction is subject to customary closing conditions.

Vinge’s team consisted of Johan Winnerblad, Kristina Ekberg, Jesper Schönbeck, Rikard Lindahl and Malin Malm Waerme.
 

Related

Vinge advises Bridgepoint in its acquisition of Safe Life

Vinge advises Bridgepoint in its agreement to acquire a significant controlling stake in Safe Life, a global leader in the distribution of automated external defibrillators (AEDs), in a transaction that values the company at c. €500 million.
June 16, 2025

Vinge advises Armada Investment AG on its investment in Studsvik

Armada Investment AG, the Zurich-based entrepreneurial investment firm led by Daniel S. Aegerter, has increased its shareholding in Studsvik to 29.9% of outstanding shares. The investment builds on Armada's initial 9.9% stake acquired in February 2025. The shares of Studsvik are admitted to trading on Nasdaq Stockholm. Armada has invested across the nuclear supply chain for over a decade, with portfolio companies including Oklo, Commonwealth Fusion Systems, Proxima Fusion, Last Energy, and Blykalla.
June 16, 2025

Vinge advises Karl Hedin and minority owners on the sale of Toftani Metsanduse OÜ to OÜ Metsavennaskond

Vinge has advised Karl Hedin and the minority owners in connection with the sale of Toftani Metsanduse OÜ to OÜ Metsavennaskond.
June 13, 2025